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Early treatment with cGMP phosphodiesterase inhibitor ame-
liorates progression of renal damage.
Background. Chronic renal disease is associated with oxida-
tive stress and reduced nitric oxide availability which, in turn,
promotes hypertension and further progression of renal dam-
age. Most actions of nitric oxide are mediated by cyclic 3′,5′
guanosine monophosphate (cGMP) which is rapidly degraded
by phosphodiesterases (PDE). Therefore, we investigated if in-
hibition of PDE-5 would retard the progression of chronic renal
failure.
Methods. We studied rats with 5/6 nephrectomy treated with
sildenafil (2.5 mg/kg−1/day−1) in two experimental protocols. In
the first protocol, we started sildenafil therapy immediately after
renal ablation and continued treatment for 8 weeks. Control
groups consisted of rats with renal ablation treated with drug-
free vehicle and sham-operated rats with and without sildenafil
treatment.
Results. In these studies, sildenafil treatment prevented
hypertension and deterioration of renal function, reduced his-
tologic damage, inflammation and apoptosis, delayed the on-
set of proteinuria, and preserved renal capillary integrity. In
the second protocol we compared sildenafil with losartan (7.5
mg/kg−1/day−1) and the combination of both drugs in estab-
lished renal disease, starting these drugs 4 weeks after 5/6
nephrectomy. Delayed sildenafil treatment failed to improve
proteinuria and glomerulosclerosis but ameliorated hyperten-
sion and azotemia.
Conclusion. These observations suggest that currently avail-
able PDE-5 inhibitors have potential clinical value in the treat-
ment of chronic renal disease.
The rising incidence of end-stage renal disease (ESRD)
has emerged as a major public health concern worldwide.
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The reduction in the number of nephron units by the pri-
mary disease process(es) triggers a chain of events that
result in glomerular and tubulointerstitial inflammation,
progressive losses of the remaining nephrons, and devel-
opment of chronic renal failure [1, 2]. This phenomenon is
associated with diminished nitric oxide availability which
is caused by a combination of reduced nitric oxide pro-
duction [down-regulation of nitric oxide synthase (NOS)
and diminished L-arginine uptake] [3–5], accumulation of
endogenous NOS inhibitors and depletion/inactivation
of nitric oxide by reactive oxygen species [6, 7]. The as-
sociated nitric oxide deficiency, in turn, promotes hy-
pertension and accelerates progression of renal disease
[7, 8].
Many of the biologic actions of nitric oxide are medi-
ated by cyclic 3′,5′ guanosine monophosphate (cGMP),
which is rapidly degraded by phosphodiesterases (PDE).
We, therefore, hypothesized that pharmacologic inhibi-
tion of the cGMP-specific PDE-5 may attenuate hyper-
tension and retard progression of renal disease by raising
the available pool of cGMP, despite the associated nitric
oxide deficiency. To test this hypothesis, we evaluated
the effects of sildenafil (Viagra) in prevention (start-
ing immediately after renal ablation) and in treatment
(started 4 weeks after renal ablation) of renal failure in
5/6 nephrectomized rats. In addition, we compared the
effects of sildenafil with those of angiotensin receptor 1
(AT1) blockade. We found that early sildenafil treatment
prevented hypertension and renal functional deteriora-
tion and reduced apoptosis and inflammatory damage
in the renal ablation model. When administration of
sildenafil was delayed until significant renal damage was
present, the severity of proteinuria and glomerulosclero-
sis were similar to that observed in vehicle-treated rats
but blood pressure and serum creatinine changes were
ameliorated. These observations suggest that a currently
available, relatively safe, class of pharmacologic agents
can be of potential value in the management of progres-
sive renal disease.
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METHODS
Experimental design
Studies were done in male Sprague-Dawley rats (In-
stituto Venezolano de Investigaciones Cientı´ficas, Los
Teques, Venezuela) with a weight of 250 to 350 g housed
in institutional facilities and receiving regular rat chow
(Protinal) (Purina, Valencia, Venezuela) and with free
access to water. Two experimental protocols were used.
Protocol 1 used early administration of sildenafil. Af-
ter obtaining baseline studies, subtotal renal ablation was
done in 20 rats using a single surgical procedure that in-
cluded right nephrectomy and selective infarction of two
thirds of the left kidney, as described previously [9]. Four
to five days after surgery, the rats were divided in two
groups. One group received sildenafil (2.5 mg/kg−1/day−1
in 0.5 mL of water) by gastric gavage (N = 10) and one
group received vehicle (N = 10). Since the sildenafil pow-
der is not water soluble, the dose was suspended in water
by vigorous agitation immediately prior to administra-
tion, as previously done by us in other studies with water
insoluble drugs [9]. Sham-operated animals (N = 10) had
laparotomy and manipulation of the kidneys and renal
pedicle without removal of kidney tissue. An additional
group of sham-operated rats (N = 5) were treated with
sildenafil to evaluate the effects of this drug in control
animal.
All animals were followed for 8 weeks after renal abla-
tion at the end of which were sacrificed under nembutal
anesthesia. At this time remnant kidneys were harvested,
and used for histologic and immunohistologic studies.
Protocol 2 used late administration of sildenafil. In
these studies rats were kept under observation with free
access to food and water for 4 weeks after 5/6 nephrec-
tomy. At this time, five rats were sacrificed and kidneys
were harvested for evaluation of histologic damage at
the start of therapy and the rest were randomly assigned
to the following treatment groups that were given for
a period of 4 weeks (8 weeks after 5/6 nephrectomy):
(1) sildenafil group (N = 5) that received sildenafil (2.5
mg/kg−1/day−1) by gastric gavage, (2) losartan group (N
= 5) that received losartan (7.5 mg/kg−1/day−1 by gastric
gavage), and (3) sildenafil + losartan group (N = 5) that
received both losartan and sildenafil as described before.
An additional group of sham-operated group (N = 5) rats
was used as normal controls.
Renal function, urinary cGMP,
and nitrate/nitrite excretion
Plasma creatinine and proteinuria were determined ev-
ery 2 weeks and systolic blood pressure was measured by
tail-cuff plethysmography every week as described in pre-
vious communications [10–12]. Creatinine clearance was
determined in five rats of each group at the end of the
experiments.
Urinary cGMP excretion was measured in 24-hour
urine collections obtained prior to sacrifice in rats of
protocol 1, using commercially available assay kits fol-
lowing the instructions of the manufacturers (Direct
cGMP Enzyme Immunoassay Kit (Assay Diagnostics,
Inc., Ann Arbor, MI, USA). The lower detection limit
is 88 fmol/mL. Intra- and interassay % coefficient of vari-
ation were 6.5% and 11.2%, respectively. Total urinary
nitrate/nitrite excretion [nitric oxide oxidation products
(NOx)] was determined with the Griess reaction after
conversion of nitrate to nitrite by nitrate reductase, using
a commercially available assay kit (Nitrate/Nitrite Col-
orimetric Assay Kit) (Cayman Chemical Co., Ann Arbor,
MI, USA). The lower detection limit using 80 lL sample
(200 lL assay volume) is 2.5 lmol/L.
Histology and immunohistology
Light microscopic studies were done in methyl Carnoy
or formalin-fixed, paraffin-embedded biopsies stained
with periodic acid-Schiff (PAS), hematoxylin and eosin,
and trichrome stains. Glomerulosclerosis was evaluated
in a score initially described by Raij, Azar, and Keane [13]
used in previous communications form our group [10, 12,
14]. Briefly, glomeruli were graded from 0 to +4: grade
0, normal; grade 1, <25% involvement of the glomerular
tuft; grade 2, 25% to 50% involvement of the glomerular
tuft; grade 3, 50% to 75%; and grade 4, sclerosis occupy-
ing >75% of the glomerular tuft. The glomerulosclerosis
score was obtained as follows: [(1 × number of glomeruli
with +1) + (2 × number of glomeruli with +2) + (3 ×
number of glomeruli with+3)+ (4×number of glomeruli
with +4)] × 100/total number of glomeruli examined.
Tubulointerstitial damage was scored using a 0 to 5
scale used previously [10–12] depending on the extent of
areas with tubular dilatation, interstitial infiltration, and
fibrosis (grade 0, no changes; grade 1, <10%; grade 2,
10% to 25%; grade 3, 25% to 50%; grade 4, 50% to 75%;
and grade 5, 75% to 100%), determined in successive
fields examined in the entire cortical and juxtamedullary
areas suited for evaluation of each biopsy, using computer
assisted image analysis.
Avidin-biotin-peroxidase methodology was used to
study to identify lymphocytes (CD5-positive cells),
macrophages [endothelin-1(ED-1)–positive cells], and
glomerular and peritubular capillaries and apoptosis as
described previously [15]. Immune cell infiltration in
glomeruli and tubulointerstitial regions were evaluated
separately and results were expressed as positive cells per
glomerular cross section (gcs) and positive cells per mm2,
respectively. Glomerular and peritubular capillary areas
identified by the corresponding antibody (see below)
were studied by computer image analysis and expressed
as the ratio of positive/total areas under examination in
successive fields in the cortical and juxtamedullary areas
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Table 1. Experimental protocol 1: General data prior to the beginning of treatment (5 days after surgery)
5/6 nephrectomy treated with
Sham (N = 15) 5/6 nephrectomy group (N = 10) sildenafil group (N = 10)
Body weight g 303 ± 35.1 287 ± 43.9 291 ± 49.3
Plasma creatinine mg/dL 0.42 ± 0.12a 0.97 ± 0.50 0.89 ± 0.50
Systolic blood pressure mm Hg 123 ± 6.0 123 ± 7.3 125 ± 9.1
Urinary protein excretion g/day 3.5 ± 3.5 5.03 ± 2.99 5.94 ± 1.99
Animals were randomized 5 days after renal ablation to receive vehicle (5/6 nephrectomy group) or sildenafil (5/6 nephrectomy treated with sildenafil) for a total of
8 weeks. There were no significant differences between groups at the beginning of the treatment. Sham-operated rats were subsequently divided in an untreated group
(N = 10) and a sildenafil-treated group (N = 5). ∗P < 0.05 vs. the rest.
of the biopsies. Apoptosis was determined in frozen kid-
ney sections by in situ peroxidase labeling of free 3′OH
DNA termini by a commercially available kit (ApopTag,
In Situ Apoptosis Detection Kit) (Serologicals Corpora-
tion, Norcross, GA, USA) following the directions of the
manufacturer, as described previously [16]
All histologic evaluations were done blinded with re-
spect to the group under evaluation. Computer-assisted
image analysis was done with an Olympus BX51 Sys-
tem Microscope (Olympus Corp., Miami, FL, USA) and
DP70 microscope digital camera, with software of Sigma
Pro (Leesburgh, VA, USA).
Antisera
Anti-CD5 and anti-ED-1 monoclonal antibodies
(Biosource, Camarillo, CA, USA) were used to identify
lymphocytes and macrophages, respectively. Glomerular
and peritubular capillaries were identified with panen-
dothelial monoclonal mouse antirat RECA-1 antibody
(clone HIS52) (Serotec Inc., Raleigh, NC, USA). Sec-
ondary biotin-conjugated affinity-pure antibodies with
minimal reactivity to rat serum proteins were purchased
from Accurate Chemical and Scientific Co. (Westbury,
NY, USA). Nonrelevant antibodies were used for nega-
tive control studies.
Statistical analysis
Differences between groups were evaluated by multi-
group analysis of variance (ANOVA) and Tukey post
tests. Serial determinations in the same animal were an-
alyzed by repeated measurement ANOVA. Two-tailed
P < 0.05 was considered significant. All the data are pre-
sented as mean ± SD.
RESULTS
Experimental protocol 1
Clinical parameters, renal function and blood pressure.
The clinical characteristics of the experimental groups
after surgery and prior to randomization to the treat-
ments are shown in Table 1. Body weight, blood pressure,
serum creatinine, and urinary protein excretion were sim-
ilar in the group that was to receive vehicle (5/6 nephrec-
tomy group) and the group that was to receive sildenafil
(5/6 nephrectomy treated with sildenafil group). Sham-
operated rats had essentially similar values (except for
serum creatinine) (Table 1).
The plasma creatinine was similarly elevated immedi-
ately after renal ablation in both experimental groups
but after the second week the group treated with silde-
nafil had a significant lower serum creatinine levels that
stabilized at 0.83 ± 0.10 mg/dL and remained significantly
below the levels found in the untreated group (P < 0.001)
(Fig. 1). The sham-operated rats treated with sildenafil
(not shown) had normal creatinine throughout the study
(0.42 ± 0.15 mg/dL at the end of the study).
The systolic blood pressure increased progressively
in the rats with renal ablation. In contrast, the simi-
larly nephrectomized rats treated with sildenafil main-
tained normal blood pressure throughout the experiment
(Fig. 2). The sham-operated rats treated with sildenafil
(not shown) remained normotensive during the study
(systolic blood pressure at the end of the study 123 ±
8.1 mm Hg) (see Table 2).
The development of proteinuria was reduced by silde-
nafil treatment. As shown in Figure 3, proteinuria re-
mained within normal levels until the fourth week when
it increased progressively. Nevertheless, at the end of the
experiment, the 5/6 nephrectomy treated with sildenafil
group had 50% reduction of proteinuria compared to the
untreated 5/6 nephrectomy group (P < 0.001). Urine pro-
tein in the sham-operated rats treated with sildenafil re-
mained within normal limits (values at the end of the
experiment are shown in Table 2).
The clinical parameters in the sham-operated groups
(untreated and treated with sildenafil), the 5/6 nephrec-
tomy group and the 5/6 nephrectomy treated with silde-
nafil group at the end of the experimental protocol 1
are shown in Table 2. Body weight, blood pressure, cre-
atinine clearance, and proteinuria were all improved
by sildenafil treatment. Urinary NOx and cGMP ex-
cretion were increased in the 5/6 nephrectomy treated
with sildenafil group (P < 0.01 vs. 5/6 nephrectomy)
(Table 2).
Histologic studies. Histologic studies confirmed
the renoprotection resulting from PDE-5 inhibition.
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Fig. 2. Serial determinations of systolic
blood pressure in the rats with renal ablation
receiving vehicle [5/6 nephrectomy group
(5/6 Nx group)], rats with renal ablation
treated with sildenafil (5/6 Nx.SIL), and
sham-operated rats. Sham-operated rats
treated with sildenafil (not shown) were
normotensive during the study (see Results
section and Table 2). Arrow indicates the
time of renal ablation surgery. Data are
mean ± SD. ∗P < 0.05; ∗∗∗P < 0.001 vs. 5/6
nephrectomy group.
Table 2. Clinical parameters at the end of the experimental protocol 1
Sham treated with 5/6 nephrectomy treated
Sham sildenafil (N = 5) 5/6 nephrectomy group with sildenafil group
Body weight g 479 ± 42 488 ± 40 360 ± 54a 450 ± 64b
Systolic blood pressure mm Hg 128 ± 6.1 123 ± 8.1 162 ± 12a 133 ± 9.1c
Creatinine clearance mL/min 3.08 ± 0.39 (N = 5) 3.5 ± 0.43 0.85 ± 0.26a (N = 5) 1.53 ± 0.45b (N = 6)
Proteinuria mg/day 4.9 ± 3.6 5.0 ± 3.5 91.4 ± 7.1a 48.4 ± 11.4c (N = 9)
Urinary NOx lmol/day 9. 2 ± 2.40 (N = 6) 9.8 ± 3.38 5.0 ± 1.72d (N = 9) 8.2 ± .30e
Urine cGMP
nmol/24 hours 45.1 ± 9.2 48.0 ± 8.5 19.0 ± 4.1a 37.3 ± 14.3b
nmol/mg creatinine 2.97 ± 0.64 3.11 ± 0.75 0.95 ± 0.28a 1.83 ± 0.32b
Abbreviations are: NOx, nitric oxide oxidation products (NO2 + NO3); cGMP, cyclic 3′,5′ guanosine monophosphate. The data shown are mean ± SD (N =
10), except when is specifically noted in the table. Significant differences between the 5/6 nephrectomy treated with sildenafil and 5/6 nephrectomy group and 5/6
nephrectomy group and sham-operated groups are distinguished.
aP < 0.001 vs. the sham groups.
bP < 0.01, 5/6 nephrectomy treated with sildenafil and 5/6 nephrectomy group.
cP < 0.001, 5/6 nephrectomy treated with sildenafil and 5/6 nephrectomy group.
dP < 0.01 vs. the sham groups.
eP < 0.05, 5/6 nephrectomy treated with sildenafil and 5/6 nephrectomy group.
Glomerulosclerosis (Fig. 4) and tubulointerstitial dam-
age scores (Fig. 5) were ameliorated and glomerular
and tubulointerstitial capillaries were preserved in the
sildenafil-treated rats (Fig. 6A to C).
Glomerular infiltration of lymphocytes (CD5-positive
cells) was generally absent but macrophage accumulation
(ED-1–positive cells/gcs) were increased in the vehicle
treated rats with renal ablation (0.46 ± 0.18) compared
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Fig. 3. Serial determinations of urinary pro-
tein excretion in the rats with renal abla-
tion receiving vehicle [5/6 nephrectomy group
(5/6 Nx group)], rats with renal ablation
treated with sildenafil (5/6 Nx.SIL), and sham-
operated rats. Urine protein data obtained in
the sham-operated rats treated with sildenafil
(not shown) are given in Table 2. Arrow indi-
cates the time of renal ablation surgery. Data
are mean ± SD. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗ P
< 0.001 vs. 5/6 nephrectomy group.
to the sildenafil-treated rats (0.26 ± 0.11) (P < 0.05). The
sildenafil-induced reduction in the immune cell infiltra-
tion was more significant in tubulointerstitial areas. As
shown in Figure 7, sildenafil administration reduced CD5
and ED-1 infiltration to about half of the numbers present
in the 5/6 nephrectomized rats treated with vehicle.
As shown in Figure 8, rats with renal ablation had in-
creased numbers of apoptotic cells. Treatment with silde-
nafil reduced the number of apoptotic cells to numbers
essentially similar to those found in sham-operated rats
(Fig. 8).
In all the histologic studies the findings in the sham-
operated rats treated with sildenafil were essentially sim-
ilar to those in the untreated sham-operated control
group.
Experimental protocol 2
Blood pressure and renal function. The administration
of sildenafil, losartan, and the combination of both treat-
ments ameliorated significantly the hypertension, par-
ticularly in the groups that received losartan alone and
in combination with sildenafil (Fig. 9). Serum creatinine
changes were also improved by sildenafil, losartan, and
the combination of both treatments (Fig. 10).
The effects of delayed administration of sildenafil,
losartan, and the combination of both on the proteinuria
in this model are shown in Figure 11. Proteinuria was
reduced by losartan treatment alone or in combination
with sildenafil at 6 and 8 weeks after renal ablation (P <
0.05). Sildenafil administration alone did not modify the
proteinuria that results from renal mass reduction.
Histologic studies. Glomerulosclerosis index and
tubulointerstitial damage scores in the delayed treatment
protocol are shown in Figure 12. Glomerulosclerosis (Fig.
12A) increased from the fourth to the eighth week af-
ter renal ablation in the vehicle-treated rats. Sildenafil
treated rats had essentially the same glomerulosclero-
sis index than the vehicle-treated rats while the losartan
treatment was associated with a reduction in the glomeru-
losclerosis index. Tubulointerstitial damage scores were
improved similarly in all treatment groups (Fig. 12B).
DISCUSSION
The central finding in this work is the demonstration
that early treatment with a cGMP PDE inhibitor re-
tards the progression of renal injury in the renal ablation
model. Daily administration of sildenafil started immedi-
ately after renal ablation resulted in stabilization of cre-
atinine levels, prevention of hypertension, reduction in
proteinuria as well as increments in urinary NOx excre-
tion and cGMP excretion in the 5/6 nephrectomized rats
(Table 2).
The changes in serum creatinine levels in the treated
group are not due to a reduction in the muscular mass
since the body weight of the rats at the time of sacrifice
was higher in the sildenafil-treated than in the untreated
5/6 nephrectomy group. Furthermore, creatinine clear-
ance was also significantly higher in the sildenafil-treated
5/6 nephrectomy group than in the untreated 5/6 nephrec-
tomy group (Table 2). Sildenafil administration is known
to exert a preconditioning protective effect that results
in a reduction in the extension of the experimentally in-
duced myocardial infarction [17]. However, it is unlikely
that this effect could have been responsible for a reduc-
tion in the size of the renal infarcts in the remnant kid-
ney of the 5/6 nephrectomy treated with sildenafil group
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−→
Fig. 4. Glomerulosclerosis damage score (A) in rats with renal abla-
tion [5/6 nephrectomy (5/6 Nx)] is reduced by sildenafil treatment (5/6
Nx.SIL). ∗∗P < 0.01; ∗∗∗P < 0.001. Representative microphotograph
of a glomerulus from a rat from the 5/6 nephrectomy group showing
an area of sclerosis occupying approximately 25% of the glomerular
tuft (B) is contrasted with a glomeruli from (A) and a rat from the 5/6
nephrectomy treated with sildenafil group (C) showing only focal hyper-
cellularity (arrow) and mild mesangial expansion [periodic acid-Schiff
(PAS) staining].
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Fig. 6. Staining with panendothelial monoclonal antibody (RECA-1) expressed as the ratio of positive area/total area in glomeruli (A) and
tubulointerstitial regions (B). Renal ablation [5/6 nephrectomy (5/6 Nx)] reduces and the treatment with sildenafil (5/6 Nx.SIL) prevents the loss
of glomerular and peritubular capillaries. ∗P < 0.05; ∗∗∗P < 0.001. Representative microphotographs of renal sections of a vehicle-treated rat (5/6
nephrectomy group) (C) and a sildenafil-treated rat (D) (immunoperoxidase staining).
since we started sildenafil administration 5 days after the
surgery.
The sildenafil-treated group remained normotensive
throughout the experiments, in contrast with the pro-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 5. Tubulointerstitial damage score (A) in rats with renal abla-
tion [5/6 nephrectomy (5/6 Nx)] is reduced by sildenafil treatment (5/6
Nx.SIL). ∗∗P < 0.01; ∗∗∗P < 0.001. Low magnification microphotograph
of the kidney of a vehicle-treated rat (5/6 nephrectomy group) (B)
shows areas of intense cellular infiltrate and tubular dilatation occupy-
ing 50% of tubulointerstitial area. In contrast, the kidney of a rat in the
sildenafil-treated group (C) is essentially normal [periodic acid-Schiff
(PAS) staining].
gressive hypertension induced by renal ablation in the
untreated 5/6 nephrectomy group. The severity of hyper-
tension observed in the untreated 5/6 nephrectomy group
here is essentially similar to that found in previous studies
from our group [9] and others [18] in this model of renal
ablation. Inhibition of PDE-5 is known to reduce blood
pressure in humans [19] and lower vascular resistance in
specific vascular beds [20, 21].
Amelioration of hypertension in the treated group was
likely due to a combination of increased nitric oxide
bioactivity and preservation of renal function. Increased
cGMP could partially compensate for the reduction in
nitric oxide bioavailability which is caused by depressed
production and enhanced inactivation of nitric oxide by
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Fig. 7. Tubulointerstitial immune cell infiltration is significantly re-
duced by sildenafil treatment. (A) CD5-positive cells are lymphocytes
and endothelin-1 (ED-1)–positive cells are macrophages. ∗∗P < 0.01;
∗∗∗P < 0.001 vs. the rest. Microphotographs show macrophage infiltra-
tion (ED-1–positive cells) in the vehicle-treated (B) and reduced num-
bers in the sildenafil-treated (C) rats with renal ablation (immunoper-
oxidase staining).
reactive oxygen species in uremia [7]. In turn, the nor-
malization of blood pressure must have helped to halt
progression of renal failure since the severity of glomeru-
losclerosis is directly correlated with the average systolic
blood pressure in this model [22, 23].
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Fig. 8. Apoptosis is increased in rats with renal ablation and reduced to
almost normal (sham-operated) levels by sildenafil treatment. (A) Com-
parison between sham, 5/6 nephrectomy (5/6 Nx), and 5/6 nephrectomy
plus sildenafil (5/Nx.SIL). ∗∗∗P < 0.001 vs. the rest. TUNEL is termi-
nal deoxynucleotidyltransferase (TdT)-mediated deoxyuridine triphos-
phate (dUTP) nick-end labeling. Microphotographs show increased
number of apoptotic cells in vehicle-treated rats with renal ablation (5/6
nephrectomy group) (B) in contrast with rats treated with sildenafil (C)
(frozen kidney sections, peroxidase staining).
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Fig. 9. Changes in systolic blood pressure in rats treated after 4 weeks
after 5/6 nephrectomy (5/6 Nx) (arrow). Amelioration of hypertension
in rats treated with sildenafil (5/6 Nx.SIL group), losartan (5/6 Nx.Lo),
and a combination of losartan and sildenafil (5/6 Nx.Lo + SIL group)
was evident after 3 weeks of treatment (weeks 7 and 8). aP < 0.05 vs. 5/6
nephrectomy treated with losartan and 5/6 nephrectomy treated with
sildenafil groups. bP < 0.05 vs. 5/6 Nx.SIL group and P < 0.01 vs. 5/6
nephrectomy treated with losartan and 5/6 nephrectomy treated with
both losartan and sildenafil groups.
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Fig. 10. Plasma creatinine is increased 4 weeks after 5/6 nephrectomy
(5/6 Nx) (arrow). The progressive increment in plasma creatinine in-
duced by 5/6 nephrectomy (5/6 Nx group) is ameliorated by the admin-
istration of sildenafil (5/6 Nx.SIL group), losartan (5/6 Nx.Lo), and a
combination of losartan and sildenafil (5/6 Nx.Lo+SIL group). aP <
0.05 vs. SD and P < 0.01 vs. losartan and losartan and sildenafil.
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Fig. 11. Proteinuria is present 4 weeks after 5/6 nephrectomy (5/6 Nx)
(arrow) and increases progressively afterward. Proteinuria is signifi-
cantly reduced by treatment with losartan alone (5/6 Nx.Lo group) and
in combination with sildenafil (5/6 Nx.Lo + SIL group) but not by silde-
nafil alone (5/6 Nx.SIL group). ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 vs.
5/6 nephrectomy.
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Fig. 12. Glomerulosclerosis index (A) and tubulointerstitial damage
score (B) in rats with 5/6 nephrectomy (5/6 Nx), 4 weeks after renal
ablation and after 4 weeks of treatment (8 weeks after 5/6 Nx). The
increment in glomerulosclerosis observed in the vehicle-treated group
(5/6 Nx group) from the fourth to eighth week postrenal ablation is
prevented by losartan treatment (5/6 Nx.Lo group). ∗P <0.05. However,
it was not affected by sildenafil (5/6 Nx.SIL group). Tubulointerstitial
damage is significantly reduced in all treatment groups: sildenafil (5/6
Nx.SIL group), losartan (5/6 Nx.Lo group) and combination treatment
(5/6 Nx.Lo + SIL group). ∗P < 0.05; ∗∗P < 0.01 vs. vehicle-treated rats
with renal ablation (5/6 nephrectomy group).
Attenuation of glomerular structural damage is proba-
bly responsible for the delay observed in the appearance
of proteinuria (Fig. 3). Glomerular and peritubular
capillary integrity (Fig. 6) was preserved by sildenafil
treatment. Taken in conjunction with the functional im-
provement, these findings support the observation of
Kang et al [24] who emphasized the contribution of mi-
crovascular damage to the progression of renal scarring.
It is of note that in the experiments in protocol 1,
proteinuria remained at baseline levels in the sildenafil-
treated group until the fourth week after 5/6 nephrectomy
and then increased progressively, almost in parallel, with
the proteinuria in the untreated 5/6 nephrectomy group
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(Fig. 3). It is therefore possible that the protection of-
fered by PDE-5 inhibition is less effective as the disease
increases in severity in this model.
The observed histologic improvement is in concert with
the clinical improvement in the sildenafil-treated group.
The glomerular lesions in the 5/6 nephrectomy group
were not too severe. A glomerulosclerosis index of 25,
found in the untreated 5/6 nephrectomy (Fig. 4), corre-
sponds to sclerotic lesions involving approximately one
quarter of the glomerular tuft in one quarter of the re-
maining glomeruli. Therefore, the relatively large impair-
ment of renal function observed in the 5/6 nephrectomy
group (Fig. 1) (Table 2) is more concordant with the
more severe tubulointerstitial injury that involved 25%
to 50% of the cortical and juxtamedullary regions (Fig. 5);
in agreement with studies that demonstrate that the de-
gree of renal functional loss is better correlated with the
severity of tubulointerstitial injury than with glomerular
histologic damage [25–27].
Apoptosis is increased in the remnant kidney. In-
creased number of apoptotic cells may reflect the in-
creased number of cells associated with the inflamma-
tory reaction but apoptosis has also been identified as a
mechanism of nephron loss in the renal ablation model
[28]. Sildenafil has been recently shown to have a strong
protective effect against apoptosis through a nitric oxide
signaling pathway [29] and the demonstration that that
apoptosis is reduced by the administration of sildenafil
in our studies (Fig. 8) suggests an additional potential
mechanism for the renoprotection.
Our findings in the 5/6 nephrectomy group are in agree-
ment with recent studies that have found a reduced uri-
nary cGMP in the renal ablation model [30]. In the
present studies the urinary cGMP excretion in the rats
with 5/6 nephrectomy is actually increased in relation to
the remnant renal mass since sham-operated rats excrete
only two to three times more urinary cGMP than rats
with one sixth of the renal mass remaining. This may rep-
resent an adaptive response in the rats with renal abla-
tion. The administration of sildenafil almost doubled the
cGMP excretion by the remnant kidney and this finding
is not only a consequence of PDE-5 inhibition, but also to
a large extent the result of preservation of renal function
and, hence, nitric oxide production capacity. Similarly, the
greater urinary excretion of the nitric oxide metabolites
(NOx) is most likely a reflection of improved renal func-
tion and structure in the rats with renal ablation treated
with sildenafil.
The experiments in which the treatment was delayed
were intended to evaluate the effects of PDE-5 inhibi-
tion on established renal damage. In the 5/6 nephrectomy
model, demonstrable mesangial expansion and glomeru-
losclerosis is already evident 4 weeks after renal ablation
and the histology can be improved with the combined
treatment of mycophenolate mofetil and angiotensin II
blockade [31, 32]. Our findings indicate that protein-
uria and glomerulosclerosis are similar in the sildenafil-
treated and the vehicle-treated rats with renal ablation
and the addition of sildenafil to losartan does not improve
the antiproteinuric effects of the later, which is known to
increase neuronal NOS (nNOS) in the renal cortex in the
remnant kidney [3]
The lack of improvement in glomerulosclerosis may
account for the lack of improvement in proteinuria. It
has been amply demonstrated that proteinuria is associ-
ated with progressive renal damage [33]; even though it
is a matter of dispute whether proteinuria itself is a risk
factor or a marker of disease activity [34]. Therefore, it
is reasonable to assume that rats treated with sildenafil
alone will go on to develop chronic renal failure earlier
than the rats treated with losartan, that have less pro-
teinuria and glomerulosclerosis. Nevertheless, beneficial
effects of sildenafil on the blood pressure and serum crea-
tinine levels were observed even when the drug treatment
was delayed until renal damage was already established
(experimental protocol 2). Similarly, the tubulointersti-
tial damage was less extensive with sildenafil (Fig. 12B)
pointing to a better correlation between tubulointerstitial
damage and renal function as discussed earlier.
The explanation for the better preservation of tubu-
lointerstitial structures than glomeruli by sildenafil in es-
tablished renal damage may not be discerned from the
present studies. To our knowledge, there are no stud-
ies defining the changes in glomerular hemodynamics
associated with PDE-5 inhibition. However, since such
effects would likely result from cGMP-mediated vasodi-
latation, primarily of preglomerular arterioles, it is rea-
sonable to assume that the effects of sildenafil would dif-
fer from those of the angiotensin blockers which primarily
cause postglomerular vasodilation and thereby attenuate
glomerular hyperfiltration.
Several partial explanations may be offered for the
beneficial effects of sildenafil on chronic tubulointersti-
tial injury. First, the increase in the pool of cGMP that
partially compensates for reduced nitric oxide availabil-
ity may, in part, contribute to the observed attenuation
of tubulointerstitial inflammation in the sildenafil-treated
5/6 nephrectomy animals. It is of note that nitric oxide me-
diates the vasodilatory and anti-inflammatory actions of
bradykinin which is significantly reduced in various mod-
els of renal injury. In fact, administration of kallikrein (by
gene transfer) which increases bradykinin production has
been shown to increase endothelial NOS (eNOS) activity
and attenuate inflammation, fibrosis, apoptosis, and tissue
damage [35–37]. The latter observations, which demon-
strated the beneficial effects of kallikrein-kinin-mediated
increase in nitric oxide availability, parallel the results
of the present study which demonstrated beneficial ef-
fects of enhancing cGMP-mediated nitric oxide bioac-
tivity. Second, the observed beneficial effects could be
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due to the antiapoptotic effect of sildenafil [29], as dis-
cussed earlier. In addition, as shown by Valente et al [38],
PDE inhibitors reduce the expression of collagen I and
a-smooth muscle cell actin; therefore, it is possible that
sildenafil could directly ameliorate tubulointerstitial fi-
brosis and epithelial-mesenchymal transition. Finally, the
control of blood pressure may offer an additional bene-
ficial effect, particularly in this experimental model [22,
23].
As expected, AT1 receptor blockade ameliorated pro-
teinuria and attenuated severity of the glomerular and
tubulointerstitial injury in the 5/6 nephrectomy animals.
In addition to their antihypertensive action, AT1 block-
ers attenuate oxidative stress, inflammation, and matrix
accumulation. Moreover, AT1 receptor blockade results
in up-regulation of eNOS and nNOS via angiotensin-II–
mediated activation of AT2 receptor. It is of note that
in the remnant kidney intrarenal mRNA and protein ex-
pression of inducible (iNOS), eNOS, and nNOS are all
reduced [3, 4, 39]. Thus, improved nitric oxide produc-
tion capacity with AT1 blockade may have contributed
to the beneficial effects observed in our losartan-treated
animals. The results of the present studies are in con-
cert with investigations that show that maneuvers that
enhance nitric oxide availability are renoprotective [40–
42]. In the renal ablation model administration of a ni-
tric oxide donor in association with lisinopril resulted in
amelioration of the nephropathy [43]. Yet, nitric oxide
donors may exert cytotoxicity by facilitating the forma-
tion of peroxynitrite from the interaction of nitric oxide
with superoxide [44–47] which can limit their potential
benefit in the treatment of renal disease [48]. Thus, our
study has identified a novel approach to the prevention
and amelioration of chronic renal damage that merits fur-
ther investigation.
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